Fig. 2. Impact of Trypto-CORM on growth and viability of N. gonorrhoeae. Panel A, growth of N. gonorrhoeae MS11 in RPMI + YAL + 100 μM Trypto-CORM (filled triangles), RPMI + YAL + 0.5% DMSO (filled circles), RPMI + YAL + 100 μM Trypto-CORM + 22 μM Leg-Hb (open triangles) and RPMI + YAL + 0.5% DMSO + 22 μM Leg-Hb (open circles). Panel A data are representative of at least three biological replicates. Panel B, viable numbers (colony forming units per ml (cfu ml^–1)) of N. gonorrhoeae at inoculation, after 4 h growth in the presence of 100 μM Trypto-CORM after 4 h growth in the absence of CORM, and after 4 h growth in the presence of 100 μM Trypto-CORM + 22 μM Leg-Hb. Panel B results show the mean and standard deviation from at least four biological replicates. Student's t-tests were performed to assess difference in viability between treatments. ** indicates P < 0.001. * indicates P < 0.05. Panel C, effect of [Trypto-CORM] on N. gonorrhoeae viability. Viability was tested after 4 h with Trypto-CORM at a range of concentrations and the IC₅₀ calculated as 21 ± 2 μM from a logistic fit to the data.